Bioprinter Costs & Tissue Engineering Investments: Strategic Guide to Regenerative Medicine MBA and Startup Equity Risks
72% of early-stage regenerative medicine startups failed to secure equity funding in 2023 (Regenerative Medicine Coalition), making strategic bioprinter investment